Dr. Jonathan L. Halperin is the Robert and Harriet Heilbrunn Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Zena and Michael A. Wiener Cardiovascular Institute of The Mount Sinai Medical Center. Educated at Columbia University and Boston University School of Medicine, Dr. Halperin joined the Mount Sinai faculty in 1980 and played a key role in the formation of the Cardiovascular Institute, a leading center for integrated cardiovascular research, education and patient care. He is Associate Director of the Institute and Past-President of the Society for Vascular Medicine and the New York City Affiliate of the American Heart Association.
Dr. Halperin was the recipient of the Heart of New York Award for Achievement in Cardiovascular Science and Medicine and the Jacobi Medallion, awarded in recognition of distinguished achievement in the field of medicine at the Mount Sinai Medical Center, as well as several teaching awards. He served in the past as Director of the Clinical Track Cardiovascular Fellowship Program and currently as Chair of the Committee on Faculty Appointments, Promotions and Tenure for the Icahn School of Medicine at Mount Sinai.
Dr. Halperin has authored books and journal articles in the field of cardiology and maintained a stream of clinical investigations, beginning with studies of cardiovascular hemodynamics that contributed to the development of angiotensin converting enzyme inhibition for patients with heart failure and studies of regional circulation related to the management of patients with Raynaud's Disease, mitral valve disease and intermittent claudication. He was the principal cardiologist responsible for the design and execution of the Stroke Prevention in Atrial Fibrillation (SPAF) clinical trials, sponsored by the National Institutes of Health. Clinical evidence from these trials helped to develop antithrombotic strategies to prevent stroke among the millions of people with atrial fibrillation. He served as Co-Chairman of the Executive Steering Committee of the international SPORTIF trials, which evaluated the first oral direct thrombin inhibitor for prevention of stroke in patients with atrial fibrillation and as a member of the Executive Steering Committee of the ROCKET-AF trial which evaluated the first oral factor Xa inhibitor for this indication. He is currently engaged in trials developing improved therapeutic approaches for prevention of morbid events in an array of cardiovascular disease states, including atrial fibrillation.
Widely recognized as an academic clinician, Dr. Halperin has been a role model for resident and fellow trainees in internal medicine and cardiology and recipient of two of Mount Sinai's most distinguished teaching awards, the Simon Dack Award, presented by the Fellows of the Division of Cardiology and the Solomon R. Berson Award, presented by the House Staff of the Departmentof Medicine. He has been identified repeatedly in both regional and national publications for providing high quality patient care, and engages in an active clinical practice, emphasizing traditional bedside skills and judicious application of modern cardiovascular technology.
Dr. Halperin discusses cardiovascular health for American Heart Month in The Daily Newsfeature The Daily Check Up. View the PDF.
- The Mount Sinai Hospital